NEW YORK, Sept. 8, 2021 /PRNewswire/ — Biotia, Inc., a company that delivers proprietary analytical software for infectious disease diagnostics, is experiencing rapid adoption by clinical researchers worldwide of its user-friendly software platform for the comprehensive surveillance and deeper insights into COVID-19 viral genetic variants.
Biotia’s COVID-DX software has been optimized for researchers sequencing COVID-19 clinical specimens and wastewater samples using the popular ARTIC, amplicon-based approach, as well as a hybridization-capture based method. COVID-DX includes lineage, clade and variant calling, up-to-date CDC variant classifications and insights, phylogenetic analysis, and FASTA files for downstream analysis and GISAID submission.
“As SARS-CoV-2 continues to evolve and sub-lineages of the Delta variant emerge, ongoing sequencing surveillance and advanced tools to aid researchers and clinicians in the interpretation of their results is essential. We view Biotia’s COVID-DX software as a key global tool in this mission to identify, isolate and fight infectious diseases,” said Bradley A. Connor, M.D., President of the GeoSentinel Foundation, a not-for-profit charitable foundation which supports the work of GeoSentinel, a worldwide emerging infectious disease surveillance and research network.
Biotia has also conducted extensive validation of COVID-DX by providing sequencing support to surveillance centers nationally. Leveraging COVID-DX, Biotia published a report on the first hospitalization in New York of a Delta vaccine-breakthrough case that linked SARS-CoV-2 sequence data with clinical details and outcomes.
“Our advanced technology supports NGS-based surveillance by implementing insightful variant and lineage reporting in agreement with the CDC classifications,” said Niamh B. O’Hara, Ph.D., CEO and co-founder of Biotia. “COVID-DX is being used by a wide variety of researchers in government, academia, healthcare and biopharma companies”.
Operating out of their Brooklyn-based CLIA lab, Biotia offers a complete solution for COVID-19 testing including rapid diagnostics, sequencing services, and software analytics.
About Biotia
Biotia is a health tech company located in New York, NY that leverages sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Their mission is to fight infectious disease by deploying a leading reference library of microbes worldwide. Biotia, a spinout company of Jacobs Technion-Cornell Institute at Cornell Tech has a New York State CLIA lab for COVID-19 testing affiliated with SUNY Downstate Health Sciences University.
Follow us on Twitter | Facebook | LinkedIn
View original content:https://www.prnewswire.com/news-releases/biotias-newest-software-for-sars-cov-2-genetic-surveillance-sees-rapid-adoption-by-researchers-seeking-deeper-insights-301371012.html
SOURCE Biotia
SINGAPORE, April 12, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (“MNDR” or “the Company”), a…
Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst…
SAN FRANCISCO, April 12, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS)…
Gross Margin Improved 300 basis points to 31% Year-Over-Year Adjusted EBITDA Grew 30% Year-Over-Year EPS…
Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link…
This conclusion is the result of almost 10 years of research carried out by the…